UK Inquest Links Tirzepatide to Death of 19-Year-Old Law Student

A British coroner ruled that the weight-loss drug tirzepatide contributed to the death of 19-year-old Josephine Nasr, a California law student studying in London. Nasr died of a cardiac arrhythmia in September 2025, which the inquest linked to an electrolyte imbalance caused by hypoglycemia from the medication. An empty vial was found in her dorm room, and she had a pre-existing congenital heart condition.
Key points
- Coroner Graeme Irvine concluded that Josephine Nasr died from a cardiac arrhythmia associated with myocardial bridging and an electrolyte imbalance.
- The inquest determined that tirzepatide-induced nausea and vomiting led to hypoglycemia, which caused the fatal electrolyte imbalance.
- Nasr, a second-year law student at the University of East London, was found dead in her dorm in Newham on September 23, 2025.
- An empty vial of tirzepatide was discovered near her body by university staff who performed a welfare check.
- Pathologist Alan Bates noted that Nasr had a congenital heart condition but was otherwise healthy, and the drug stress may have aggravated her condition.
Background
This case follows earlier UK regulatory reviews of GLP-1 drugs, where the Medicines and Healthcare products Regulatory Agency noted approximately 200 deaths linked to these medications, though it emphasized that reporting does not prove causation. Recent studies also indicate that women may experience greater weight loss on tirzepatide compared to men, highlighting the drug's widespread use among younger demographics.
How outlets are covering it
The Daily Mail and New York Post emphasized the direct link between the drug and the death, highlighting the empty vial found at the scene. Patch focused on the local impact, noting Nasr was from Corona, California, and a former student of Santiago High School. The Independent reported on the inquest details, while Eli Lilly, the manufacturer, reiterated that the drug is not approved for cosmetic weight loss or for patients under 18, though Nasr was 19. All sources agreed on the coroner’s conclusion but varied in their emphasis on the drug’s side effects versus the underlying heart condition.
Why it matters
This ruling highlights potential risks of GLP-1 drugs in individuals with undiagnosed or congenital heart conditions. It underscores the importance of monitoring side effects like nausea and vomiting, which can lead to severe complications such as hypoglycemia and electrolyte imbalances. The case may influence prescribing practices and safety warnings for weight-loss medications in young adults.
What to watch
Regulators may review safety data for tirzepatide in young adults with pre-existing heart conditions. Eli Lilly may face increased scrutiny regarding the marketing and prescribing of Mounjaro and Zepbound. Families and advocates may push for stricter guidelines on the use of weight-loss drugs in students and young adults.
- Coroner Links California Law Student’s Death To Weight Loss Drug Tirzepatide Where Is The Buzz
- Coroner links teenage student’s death to weight-loss drug Mounjaro The Times
- RivCo Teen's Death Tied To Weight Loss Shot: Report Patch
- Sudden death of California law student studying abroad linked to popular weight loss shot, inquest heard New York Post
- London law student died in halls of residence after taking weight loss drug, inquest told independent.co.uk
Want the full story? Read the original reporting
Read on Where Is The Buzz